Key result
DNA and adenoviral vaccines elicit antibodies against most SARS-CoV-2 variants but JN.1 completely escapes neutralization.
Why the study?
The immune evasion of emerging SARS-CoV-2 variants significantly undermines current vaccination efforts, necessitating identification of optimal booster candidates against circulating JN.1 variant.
Population
Preclinical models and immunized cohorts exposed to SARS-CoV-2 variants
Comparison
DNA prime-DNA boost vs DNA prime-adenoviral vectored vaccine boost by intramuscular or intranasal immunization
Design
Preclinical immunogen characterization study
Authors
Loading...
May guide preclinical booster selection against JN.1; leaves open clinical efficacy and durability in humans.
The JN.1 SARS-CoV-2 variant exhibits significant immune evasion, making it intrinsically difficult to elicit neutralizing antibodies compared to XBB and EG.5.1 variants.
Fan et al. (2024) studied SARS-CoV-2. DNA prime-DNA boost or DNA prime-adenoviral vectored vaccine boost was evaluated on Neutralizing antibody and T cell responses. DNA and adenoviral vectored vaccine regimens elicited neutralizing antibodies against most SARS-CoV-2 variants, but the JN.1 strain completely escaped neutralization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: